Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
11.94
Price to sales ratio
1.29

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
2318
CRON
Cronos Group Inc. - Common Share
3.38 USD-0.29%+2.11%+16.96%+33.07%1.25 B USD
2436
PCRX
Pacira BioSciences, Inc. - Common Stock
25.76 USD-0.27%+4.72%-4.10%+18.00%1.03 B USD
2592
COLL
Collegium Pharmaceutical, Inc. - Common Stock
25.35 USD-4.12%-6.39%-29.01%-27.86%825.28 M USD
2724
IRWD
Ironwood Pharmaceuticals, Inc. - Class A Common Stock
4.13 USD-2.59%-3.05%+5.09%+215.27%682.44 M USD

Frequently asked questions about Amphastar Pharmaceuticals, Inc.

What is the Amphastar Pharmaceuticals, Inc. stock price today?

The current price of Amphastar Pharmaceuticals, Inc. (AMPH) is 22.01. Over the past 24 hours, the stock has changed by +0.59%. Follow the AMPH chart for real-time price dynamics.

What is the stock ticker of Amphastar Pharmaceuticals, Inc.?

Amphastar Pharmaceuticals, Inc. trades under the ticker AMPH. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Amphastar Pharmaceuticals, Inc. stock going up?

AMPH has changed by +1.90% over the last week, +8.16% over the last month, and -9.72% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Amphastar Pharmaceuticals, Inc.?

Amphastar Pharmaceuticals, Inc. currently has a market capitalization of 936.26 M. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

What were Amphastar Pharmaceuticals, Inc. earnings last quarter?

Last quarter, Amphastar Pharmaceuticals, Inc. reported earnings of 0.69 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Amphastar Pharmaceuticals, Inc. revenue for the last quarter?

Amphastar Pharmaceuticals, Inc. reported quarterly revenue of 183.9 M. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Amphastar Pharmaceuticals, Inc. net income for the last quarter?

Amphastar Pharmaceuticals, Inc. reported net income of 30.35 M for the last quarter. The previous quarter showed 6.42 M, which means net income changed by +372.71%.

How many employees does Amphastar Pharmaceuticals, Inc. have?

As of the latest available data, Amphastar Pharmaceuticals, Inc. has 1 976 employees. Workforce size can provide additional context about the company's scale and operations.

What is Amphastar Pharmaceuticals, Inc. EBITDA?

Amphastar Pharmaceuticals, Inc. EBITDA is 54.04 M, and its EBITDA margin is 29.39%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Amphastar Pharmaceuticals, Inc. stock?

You can buy Amphastar Pharmaceuticals, Inc. (AMPH) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Amphastar Pharmaceuticals, Inc. stock?

Investing in Amphastar Pharmaceuticals, Inc. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the AMPH chart and related analysis on metatrader.com as part of your research.

Amphastar Pharmaceuticals, Inc. - Common Stock

Amphastar Pharmaceuticals is a publicly traded American speciality pharmaceutical company. It was incorporated in May 2004 and primarily develops, manufactures, and sells inhalation and intranasal products. One of its products is naloxone, an injectable generic drug that treats opioid overdose, and the company was criticized when it doubled the price of the drug from around $20 to $40 in 2015 during the opioid epidemic. In February 2017, the FDA rejected the company's application to market a device that delivers naloxone intranasally. In March 2018, the company won a patent infringement lawsuit brought against it by Momenta Pharmaceuticals and Sandoz Inc in an ongoing antitrust case. In April 2023, Amphastar Pharmaceuticals bought Baqsimi from Eli Lilly in a deal worth over $1bn.

News